Acutaas Chemicals logs 59% revenue jump, battery plant starts supply
Q1 revenue at ₹329.7 crore, up 59% YoY. Battery chemicals plant begins commercial supply. Management retains 25% growth guidance for FY27 with stable margins.
— 1 earlier story on Acutaas Chemicals Ltd. →What's new
- Revenue rose 59% YoY to ₹329.7 crore in Q1 FY27.
- Battery chemicals plant commenced commercial supply.
- Management reiterated 25% revenue growth guidance for FY27 with stable margins.
Why this matters
The 59% growth builds on a trailing revenue increase of 40% and a PAT jump of 114%. The battery chemicals plant adds a new high-growth leg, but the stock trades at a trailing P/E of 75.6x, leaving little room for error. The transcript itself is a routine disclosure; the numbers were already out.
What we're watching
- Ramp-up of battery chemicals revenue in coming quarters.
- Progress on the Indichem semiconductor JV in Korea.
- Phase-out timeline for commodity chemicals.
The full read
Acutaas Chemicals delivered Q1 revenue of ₹329.7 crore, up 59% year-on-year, and the battery chemicals plant has begun commercial supply. Management kept its 25% full-year growth guidance intact, with stable margins. The numbers are strong — especially against a trailing revenue growth of 40% and PAT growth of 114%. But the stock trades at 75.6x trailing earnings. The transcript, filed after the board-approved results, is a procedural readout; the market already had the headline numbers. The open question is how fast the battery chemicals and CDMO ramp-up will translate into higher earnings amid the shift away from commodity chemicals.
Questions answered
- How did Acutaas perform in Q1 FY27?
- Revenue was ₹329.7 crore, up 59% year-on-year. Profit details were not separately highlighted but management guided for stable margins. The company built on FY26 full-year revenue of ₹1,339 crore.
- What is the status of the battery chemicals plant?
- Commercial supply has commenced from the new battery chemicals plant. Management did not disclose revenue contribution or capacity utilisation in the transcript.
- What is the revenue guidance for FY27?
- Management reiterated 25% revenue growth guidance for FY27 with stable margins. The guidance matches the Q1 performance trajectory.
- Why did the transcript filing not move the stock?
- The transcript is a backward-looking procedural disclosure. Key information like revenue and guidance was already shared during the results call and the board approval on the same day. The market had already absorbed the data.
- What risks does the company face?
- Acutaas carries a high trailing P/E of 75.6x. It also recently faced a GST anti-evasion raid in June 2026, which could pose compliance or financial risks.
Acutaas Chemicals Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on ACUTAAS →- 28 Jul 2026 · 6:56 PM IST Acutaas Chemicals logs 59% revenue jump, battery plant starts supply
- 36d ago Acutaas Chemicals' facility raided by GST anti-evasion dept